Furthermore, we have hypothesized that treatment with BRAF-I would induce an increase in IFNRA1 expression, which in turn would lead to an increase in the sensitivity of melanoma to the antitumor activity of IFN-α. The gene discussed is IFNA2; the disease is melanoma.